FMC Stock Analysis: FMC | NYSE
Agricultural Inputs | NYSE, USA | Market Cap: 1.419m USD | 12M Return: -64% | US3024913036 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 30.6M
EPS Trend: -48.7%
Qual. Beats: 0
Rev. Trend: -91.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
FMC Corporation is a U.S.-based agricultural sciences company that develops, manufactures, and sells crop protection chemicals across Latin America, North America, Europe, the Middle East, Africa, and Asia. Its product portfolio spans insecticides, herbicides, and fungicides, with additional offerings in biologicals, crop nutrition, and seed treatment. FMC distributes its products through a mix of its own sales organization, alliance partners, independent distributors, and sales representatives. Founded in 1883 and headquartered in Philadelphia, Pennsylvania, the company is classified within the GICS Materials sector under Fertilizers & Agricultural Chemicals.
The crop protection industry is a key segment of the global agricultural inputs market, providing products that help farmers safeguard yields against pests, weeds, and diseases. The sector is dominated by a handful of multinational agrochemical companies, and demand is closely tied to global planted acreage, commodity prices, and weather conditions. Within this market, the biologicals sub-segment-products derived from natural sources-has emerged as a growing area of investment, driven by farmer interest in integrated pest management and more sustainable input programs.
- Brazil crop protection volumes drive Latin America revenue growth
- Biologicals portfolio expands with double-digit sales growth
- EU pesticide regulations threaten product mix and margins
- Raw material and freight costs continue pressuring product margins
| Net Income: -2.76b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 2.23 > 1.0 |
| NWC/Revenue: 72.26% < 20% (prev 45.85%; Δ 26.41% < -1%) |
| CFO/TA 0.02 > 3% & CFO 140.7m > Net Income -2.76b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (125.3m) vs 12m ago -0.16% < -2% |
| Gross Margin: 35.29% > 18% (prev 39.20%; Δ -3.91% > 0.5%) |
| Asset Turnover: 30.33% > 50% (prev 33.60%; Δ -3.27% > 0%) |
| Interest Coverage Ratio: -0.39 > 6 (EBIT TTM -640.0m / Interest Expense TTM 1.65b) |
| A: 0.26 (Total Current Assets 4.73b - Total Current Liabilities 2.38b) / Total Assets 9.14b |
| B: 0.40 (Retained Earnings 3.68b / Total Assets 9.14b) |
| C: -0.06 (EBIT TTM -640.0m / Avg Total Assets 10.7b) |
| D: 0.22 (Book Value of Equity 1.64b / Total Liabilities 7.48b) |
| Altman-Z'' = 2.83 = A |
| DSRI: 0.86 (Receivables 2.07b/3.08b, Revenue 3.25b/4.13b) |
| GMI: 1.11 (GM 39.20% / 35.29%) |
| AQI: 0.87 (AQ_t 0.42 / AQ_t-1 0.48) |
| SGI: 0.79 (Revenue 3.25b / 4.13b) |
| TATA: -0.32 (NI -2.76b - CFO 140.7m) / TA 9.14b) |
| Beneish M = -3.31 (Cap -4..+1) = AA |
As of September 05, 2026, the stock is trading at USD 12.97 with a total of 2,583,625 shares traded. Over the past week, the price has changed by +14.47%, over one month by +22.94%, over three months by +7.14% and over the past year by -63.98%.
Current recommended Stop Loss: 11.60 (which is 10.6% or 2.1 ATR below the current price).
FMC has received a consensus analysts rating of 3.55. Therefore, it is recommended to hold FMC.
- StrongBuy: 5
- Buy: 2
- Hold: 12
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 13.4 | 3.5% |
P/E Forward = 9.7752
P/S = 0.4364
P/B = 0.8156
P/EG = 0.4579
Revenue TTM = 3.25b USD
EBIT TTM = -640.0m USD
EBITDA TTM = -481.3m USD
Long Term Debt = 3.95b USD (from longTermDebt, last quarter)
Short Term Debt = 326.3m USD (from shortTermDebt, last quarter)
Debt = 4.40b USD (from shortLongTermDebtTotal, last quarter) + Leases 123.9m
Net Debt = 3.93b USD (calculated: Debt 4.40b - CCE 476.6m)
Enterprise Value = 5.35b USD (1.42b + Debt 4.40b - CCE 476.6m)
Interest Coverage Ratio = -0.39 (Ebit TTM -640.0m / Interest Expense TTM 1.65b)
EV/FCF = 32.33x (Enterprise Value 5.35b / FCF TTM 165.4m)
FCF Yield = 3.09% (FCF TTM 165.4m / Enterprise Value 5.35b)
FCF Margin = 5.09% (FCF TTM 165.4m / Revenue TTM 3.25b)
Net Margin = -84.83% (Net Income TTM -2.76b / Revenue TTM 3.25b)
Gross Margin = 35.29% ((Revenue TTM 3.25b - Cost of Revenue TTM 2.10b) / Revenue TTM)
Gross Margin QoQ = 39.45% (prev 32.51%)
Tobins Q-Ratio = 0.58 (Enterprise Value 5.35b / Total Assets 9.14b)
Interest Expense / Debt = 37.55% (Interest Expense 1.65b / Debt 4.40b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -505.6m (EBIT -640.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.99 (Total Current Assets 4.73b / Total Current Liabilities 2.38b)
Debt / Equity = 2.69 (Debt 4.40b / totalStockholderEquity, last quarter 1.64b)
Debt / EBITDA = -8.16 (negative EBITDA) (Net Debt 3.93b / EBITDA -481.3m)
Debt / FCF = 23.75 (Net Debt 3.93b / FCF TTM 165.4m)
Total Stockholder Equity = 2.33b (last 4 quarters mean from totalStockholderEquity)
RoA = -25.73% (Net Income -2.76b / Total Assets 9.14b)
RoE = -118.6% (Net Income TTM -2.76b / Total Stockholder Equity 2.33b)
RoCE = -10.19% (EBIT -640.0m / Capital Employed (Equity 2.33b + L.T.Debt 3.95b))
RoIC = -7.30% (negative operating profit) (NOPAT -505.6m / Invested Capital 6.93b)
WACC = 24.85% (E(1.42b)/V(5.82b) * Re(9.90%) + D(4.40b)/V(5.82b) * Rd(37.55%) * (1-Tc(0.21)))
Discount Rate = 9.90% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 5.18 | Cagr: 0.13%
[DCF] Terminal Value 36.82% ; FCFF base≈165.4m ; Y1≈166.1m ; Y5≈175.9m
[DCF] Fair Price = N/A (negative equity: EV 722.6m - Net Debt 3.93b = -3.21b; debt exceeds intrinsic value)
EPS Correlation: -48.66 | EPS CAGR: -12.21% | SUE: 0.77 | # QB: 0
Revenue Correlation: -91.10 | Revenue CAGR: -11.72% | SUE: -0.13 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.11 | Chg30d=-82.40% | Revisions=-80% | Analysts=14
EPS current Year (2026-12-31): EPS=1.29 | Chg30d=-21.96% | Revisions=-80% | GrowthEPS=-56.4% | GrowthRev=+3.4%
EPS next Year (2027-12-31): EPS=1.64 | Chg30d=-18.66% | Revisions=-82% | GrowthEPS=+27.1% | GrowthRev=+4.5%
[Analyst] Revisions Ratio: -93% (up=0, down=38)